CTLA4 and neoplasm: We observed a significant delay in tumor growth in all mice and complete tumor regression in approximately 37% of mice treated with DNA-PKi plus immune adjuvants, and 100% tumor regression when paired with anti–PD-1/–CTLA-4 blockade.